SUMMARY This study investigated the effect of colloidal bismuth subcitrate and cimetidine on Campylobacter pylori in peptic disease. In 74% of 135 patients with peptic disease diagosed at endoscopy C pylon was detected before treatment. Compared with cimetidine, colloidal bismuth subcitrate significantly decreased the incidence ofCpylori after six weeks oftreatment (p<O-OO1). In the colloidal bismuth subcitrate group, subsequent healing of the lesion was correlated with the clearance of C pylon, unlike in the cimetidine group. C pylon was strongly associated with the presence of histological gastritis, which was decreased by colloidal bismuth subcitrate (p<0001).
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Campylobacter pylori was first isolated from gastric mucosa by Warren and Marshall in 1983 .' A number of studies have shown an association between the presence of these organisms and duodenal ulcer.`3 There is a strong correlation between C pylori and chronic non-autoimmune histological gastritis. 3' The role that these organisms might play in the aetiology and pathogenesis of peptic disease remains unclear.
Colloidal bismuth subcitrate (CBS) has been used successfully in the treatment of peptic disease for over two decades. It is classified as a mucosal protecting agent but its mode of action is not fully understood. Colloidal bismuth subcitrate has an antibacterial action6 and its efficacy in the treatment of peptic disease may be explained by the eradication of C pylori. Cimetidine, a H2 histamine receptor antagonist causes an increase in the gastric pH and may facilitate the multiplication of C pylori. Neither CBS or cimetidine affect the natural history of peptic disease, but patients treated for duodenal ulcer with CBS have a lower relapse rate. '8 The purpose of this study was to investigate the effect of CBS and cimetidine on C pylori and histological gastritis and to determine the relationship between the presence of this bacterium and healing in patients with peptic disease. (Table 1) . There was an excellent correlation between the three techniques with 80% of patients being positive by two or three of the methods.
C pylori was isolated in almost all patients with duodenal and gastric ulcer, but the incidence was lower in oesophagitis and endoscopic gastritis ( Table  1 ). The isolation of C pylori was not significantly associated with any patient variable.
In comparison with cimetidine, there was a highly significant decrease (82%-40%) in the incidence of C pylori after six weeks treatment with CBS ( Table  2 ). The isolation rate for the cimetidine group There was no relationship between the presence of endoscopic and histological gastritis. Sixty seven per cent of patients had histological gastritis, the highest incidence (74%) being in the duodenal ulcer group. The incidence in patients with gastric ulcer, oesophagitis and endoscopic gastritis was 70%, 56%, and 61% respectively. Table 4 documents the relationship between Cpylori status and histological gastritis. There was a strong correlation between the presence of histological gastritis and the presence of C pylori. Severe gastritis was seen in the presence of C pylori but the organism was not detected in a histologically normal stomach. After six weeks of therapy with CBS, there was a significant improvement in the severity of histological gastritis (Table 5 ) but cimetidine had no effect on the grade of histological gastritis, however, irrespective of its effect on the primary lesion. The effect of CBS on histological gastritis was directly correlated with its ability to eradicate Cpylori.
Discussion
In 74% of patients with peptic disease, C pylori was detected in gastric antral mucosa. This is in agreement with previous studies.23 Almost all patients with duodenal ulcer had C pylori in the gastric antrum, a finding that agrees with that of Marshall and others.'
The presence of Cpylori was not associated with any epidemiological variable in this study. Five patients only had taken antibiotics in the three months before the study although none at the time of endoscopy, but such therapy does not appear to have affected C pylori status. There is strong evidence that antibiotic therapy alone may be insufficient to eradicate Cpylori in vivo. 9 The known correlation between histological gastritis and the presence of CpyloriP5 is borne out by the data presented here, where 70% of those with active gastritis were infected, while 76% of those with normal mucosa were not. Many studies have documented an antibacterial effect for CBS against C pylori in vitro6l4 and there are some preliminary reports of CBS having a similar effect in vivo.9145 The exact mode of action of CBS is unknown,'6"7 but it is as effective as cimetidine in the treatment of peptic ulcer disease.'8 This study examined the effect of CBS, which has no systemic effects'6 on lesion healing, C pylori status, and histological gastritis with a group of matched patients on cimetidine serving as a control group. The results confirm the efficacy of both agents in treating peptic disease. Colloidal bismuth subcitrate and cimetidine had different effects on Cpylori. Overall, the Cpylori status of patients on cimetidine did not change. The seven patients who lost C pylori after treatment may be explained by its weak antibacterial effect6 or sampling error. Five patients became colonised while The data now accumulated strongly support a role for C pylori in the pathogenesis of chronic histological gastritis which is not associated with immune mechanisms'9 or excessive alkaline reflux.20 Marshall and colleagues have suggested that the ingestion of Cpylori induces an acute gastrointestinal disturbance which in a proportion of patients leads to chronic gastritis.2' The clinical significance of histological gastritis has yet to be determined, however, as it can be present in patients who are asymptomatic and have a normal endoscopy. This study shows a strong correlation between the presence of C pylori and histological gastritis and an association between the healing of histological gastritis and the eradication of C pylori on CBS only. This finding, in addition to suggesting a possible mode of action for CBS, lends support to Marshall's hypothesis.
C pylori is associated with peptic disease (except oesophagitis) but it is difficult to determine its precise role in pathogenesis. Chronic antral gastritis is an almost constant feature in peptic ulcer disease.22 23 Cpylori is often found in association but the organism has not been detected on metaplastic small intestinal type epithelium in the stomach or on normal duodenal epithelium. The intense urease activity of C pylori may initiate the ulcer sequence by breaking the mucosal barrier in the stomach24 and a similar process may occur in the duodenum. By persisting in diseased mucosa, C pylori may continue the ulcerogenic process because it is found in gastric metaplasia of the duodenum" 2 which is seen in endoscopically healed ulcers.25 Ulcer relapse is more common after cimetidine than CBS therapy78 possibly because CBS eradicates Cpylori and hence alters the natural history of the condition. Furazolidone has been shown to heal peptic ulcers and to lower the relapse rate after treatment.2627 This may imply that antibiotics should be incorporated into the management of these conditions in order to completely eradicate Cpylori.28
While it is premature to suggest that Cpylori is the unifying agent in the histological gastritis-peptic ulcer spectrum, these preliminary results are exciting and suggest that a cure for peptic disease may be at hand. 
